Preprint available on bioRxiv
A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity
We describe our ex vivo platform for assessing immune checkpoint inhibitor response using live tumor tissue while preserving large areas of the contiguous native tumor microenvironment. Using a sequential treatment strategy, we mitigate tumor heterogeneity challenges exacerbated when tissue amount is scarce.